United Therapeutics | UTHR - Loan Capital


United Therapeutics reported $100M in Loan Capital for its fiscal quarter ending in June of 2024.





Loan Capital Change Date
Ardelyx USD 202.83M 696K Dec/2025
Baxter International USD 8.62B 852M Mar/2026
Bayer EUR 30.68B 1.15B Mar/2026
BioCryst Pharmaceuticals USD 395.2M 33.48M Mar/2026
Biogen USD 6.29B 1.7M Mar/2026
BioMarin Pharmaceutical USD 1.43B 833.11M Mar/2026
Emergent BioSolutions USD 446.5M 1.7M Dec/2023
Esperion Therapeutics USD 457.65M 9.5M Dec/2025
Gilead Sciences USD 20.86B 1.27B Mar/2026
GlaxoSmithKline GBP 14.01B 696M Mar/2026
Halozyme Therapeutics USD 1.94B 206.73M Mar/2026
Insmed USD 542.22M 1.25M Mar/2026
Ionis Pharmaceuticals USD 1.91B 9M Mar/2026
J&J USD 37.53B 1.91B Mar/2026
Lexicon Pharmaceuticals USD 49.68M 276K Mar/2026
Moderna USD 603M 7M Mar/2026
Omeros USD 403.72M 27.2M Jun/2024
Pfizer USD 60.57B 1.08B Mar/2026
PTC Therapeutics USD 286.94M 1.74B Mar/2026
Regeneron Pharmaceuticals USD 1.99B 719.7M Mar/2026
Sangamo BioSciences USD 0 0 Jun/2022
Sarepta Therapeutics USD 838.16M 9.19M Mar/2026
Teva Pharmaceutical Industries USD 14.02B 971M Mar/2026
United Therapeutics USD 100M 100M Jun/2024
Vertex Pharmaceuticals USD 106.7M 4.7M Dec/2025